Post by Gubra

Heading to the American Diabetes Association Scientific Sessions 2026? Gubra will be at #ADA2026 from June 5–8, bringing together scientists from both our Biotech and CRO teams. Representing Gubra in New Orleans will be Louise S. Dalbøge, Thomas Langenickel, Hanne Haahr, Ralf Elvert, Marco Tozzi, and Simone B.. From Gubra Biotech, we look forward to reconnecting with colleagues in the field and presenting preclinical data from our UCN2 program. Chief Science Officer Louise S. Dalbøge will give an oral presentation on Gubra’s UCN2 program, focusing on GUB-UCN2 as monotherapy and in combination with semaglutide, and its potential to increase muscle mass, reduce fat mass, and improve metabolic outcomes in aged diet-induced obese rats. Session: Preserving Lean Mass with GLP-1R Therapy: Preclinical Obesity Studies Presentation no.: 1103-OR Date/time: Friday, June 5, 2026, 2:30–2:45 PM Location: 343, Level 3 From Gubra CRO, our scientists will present new findings on energy expenditure and translational obesity models during the Monday poster session: Marco Tozzi, Principal Scientist: A Novel Humanized Glucagon-Like Peptide 1 Receptor Mouse Model for Translational Drug Development Poster no.: 2567-P Date/time: Monday, June 8, 2026, 12:30–1:30 PM Simone Bossi, Senior Scientist: Differential Effects of Semaglutide, Tirzepatide, and Survodutide on Energy Expenditure in Obese Mice under Thermoneutrality Poster no.: TBA Date/time: Monday, June 8, 2026, 12:30–1:30 PM Reach out to our team to connect at ADA, discuss our presentations, or hear more about how Gubra is advancing translational obesity research – from lean mass preservation to next-generation incretin therapies. Explore Gubra's ADA posters and book a meeting with our CRO-team in New Orleans here: https://lnkd.in/dgjSuxnH #ADA2026 #ADA #ObesityResearch #MetabolicDisease #DrugDevelopment #PreclinicalResearch #BeyondGLP1 #Biotech #CRO